India, April 1 -- Compass Therapeutics, Inc (CMPX), Tuesday announced promising top-line results from its Phase 2/3 COMPANION-002 trial, evaluating tovecimig, formerly CTX-009 combined with paclitaxel in patients with advanced biliary tract cancer.
The study demonstrated a statistically significant improvement in objective response rate, with 17.1 percent of patients responding to the combination therapy compared to 5.3 percent for paclitaxel alone.
BTC affects about 23,000 patients in the U.S. annually, and most have limited second-line treatment options. The study enrolled 168 patients, with those in the experimental arm receiving tovecimig plus paclitaxel. The trial is ongoing, with secondary endpoints-including progression-free surviv...